Hologic, Inc. (NASDAQ:HOLX) Stake Boosted by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.0% in the 4th quarter, Holdings Channel reports. The firm owned 4,403,220 shares of the medical equipment provider’s stock after purchasing an additional 129,035 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Hologic were worth $322,272,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of HOLX. General Partner Inc. acquired a new position in Hologic during the 4th quarter valued at approximately $26,000. Groupama Asset Managment grew its position in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC lifted its position in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on HOLX. Royal Bank of Canada decreased their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Stephens reiterated an “overweight” rating and issued a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Wolfe Research began coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Finally, Evercore ISI decreased their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

Shares of Hologic stock opened at $61.48 on Thursday. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock has a market cap of $13.80 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The business has a fifty day simple moving average of $65.56 and a 200-day simple moving average of $73.57.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.